The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
Elias Jabbour
No relevant relationships to disclose
Hagop M. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
Deborah A. Thomas
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Jorge E. Cortes
No relevant relationships to disclose
Stefan Faderl
Consultant or Advisory Role - Genzyme; Sanofi
Honoraria - Genzyme; Sanofi
Research Funding - Genzyme; Sanofi
Naveen Pemmaraju
No relevant relationships to disclose
Tapan M. Kadia
No relevant relationships to disclose
Rebecca S. Garris
No relevant relationships to disclose
Guillermo Garcia-Manero
No relevant relationships to disclose
Gautam Borthakur
No relevant relationships to disclose
William G. Wierda
Consultant or Advisory Role - Celgene; Genentech; Merck; Sanofi
Honoraria - Celgene; Genentech; GlaxoSmithKline
Research Funding - Abbott Laboratories; Genentech; GlaxoSmithKline
Susan Mary O'Brien
Research Funding - ARIAD